ALHEMO

This brand name is authorized in Lithuania, United States

Active ingredients

The drug ALHEMO contains one active pharmaceutical ingredient (API):

1 Concizumab UNII 68603V9EAF - CONCIZUMAB

Concizumab is an anti-tissue factor pathway inhibitor (anti-TFPI) antibody. TFPI is an inhibitor of factor Xa (FXa). Concizumab binding to TFPI prevents TFPI inhibition of FXa. The increased FXa activity prolongs the initiation phase of coagulation and allows sufficient thrombin generation for effective haemostasis. Concizumab acts independently from FVIII and FIX. Read about Concizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ALHEMO Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02BX10		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1102109, 1102110, 1102111, 1102112, 1102113, 1102114, 1102115
Country: US	FDA, National Drug Code	Identifier(s): 0169-2080, 0169-2081, 0169-2084